Compatibility of different PET/CT criteria in evaluating treatment response and survival in non-small cell lung cancer patients treated with immunotherapy [0.03%]
免疫治疗的非小细胞肺癌患者接受治疗反应和生存的不同PET/CT标准的一致性评估
İmdat Eroğlu,Uğuray Aydos,Yasemin Ünlüer Ateş et al.
İmdat Eroğlu et al.
Background: Several PET/CT-based criteria have been developed to assess immunotherapy (IT) response, but their correlation with overall survival (OS) and mutual concordance in non-small-cell lung cancer (NSCLC) remains un...
Genotoxicity of cancer therapies and the risk of secondary malignancies: toward personalized prevention [0.03%]
癌症治疗的遗传毒性与继发性恶性肿瘤的风险：迈向个性化预防
Olorunfemi Raphael Molehin,Amos Tomiwa Afolabi
Olorunfemi Raphael Molehin
The evolution of cancer therapies has dramatically improved patient survival but has also revealed a critical challenge: the long-term genotoxic effects that can lead to secondary primary malignancies (SPMs). This review synthesizes current...
The evolution of cellular-based immunotherapy in the treatment of gastric cancer: an overview of clinical trials [0.03%]
基于细胞的免疫治疗在胃癌治疗中的演变：临床试验概览
Lang Wu,Jasur Rizaev,Khaled Fahmi Fawy et al.
Lang Wu et al.
Despite advances in patients' healthcare, gastric cancer remains a major health concern around the world with a high annual incidence rate and mortality. This highlights the urgent need to develop more effective therapeutic strategies, part...
Disproportionality analysis of hematologic adverse events associated with trastuzumab deruxtecan using the Japanese pharmacovigilance database [0.03%]
利用日本药物警戒数据库对德鲁替康与血液学不良事件不比例分析研究
Yuko Kanbayashi,Risa Morioka,Koichi Takayama et al.
Yuko Kanbayashi et al.
Purpose: To evaluate the disproportionality, time to onset, reporting frequency, and outcomes of hematologic AEs associated with trastuzumab deruxtecan (T-DXd) using data from the Japanese Adverse Drug Event Report databa...
Clinical efficacy and safety of Cadonilimab immunotherapy in recurrent or metastatic gynecological malignancies: a retrospective study [0.03%]
卡度尼利单抗免疫治疗复发或转移性妇科肿瘤的临床疗效及安全性回顾性研究
Lulu Lou,Jiahong Jiang
Lulu Lou
Background: Cadonilimab is a novel PD-1/CTLA-4 bispecific antibody approved for cervical cancer treatment in China in 2022. We conducted a retrospective study to investigate the efficacy and safety of Cadonilimab in patie...
CCDC137 affects sorafenib resistance in hepatocellular carcinoma cells by activating the AKT/mTOR signaling pathway [0.03%]
CCDC137通过激活AKT/mTOR信号通路影响肝癌细胞索拉非尼耐药性
Hanchuan Tao,Yu Wang,Fang Wang et al.
Hanchuan Tao et al.
Background: Hepatocellular carcinoma (HCC) is treated with sorafenib as a first-line treatment; however, resistance reduces its clinical effectiveness. It has been demonstrated that CCDC137 influences cell survival and pr...
Mechanistic insights into HAGLROS-mediated therapy resistance in ovarian cancer [0.03%]
HAGLROS介导的卵巢癌治疗抵抗的相关机制研究
Mohadeseh Sheykhi-Sabzehpoush,Hamed Abedzeydi,Maryam Khombi Shooshtari et al.
Mohadeseh Sheykhi-Sabzehpoush et al.
Ovarian cancer is a deadly gynecological malignancy, often detected late with frequent recurrence and treatment resistance. Non-coding RNAs, particularly long non-coding RNAs (lncRNAs), are now recognized as crucial regulators of cancer pat...
Is mortality truly higher for oncology patients admitted to intensive care units? A matched cohort observational study [0.03%]
一项配对队列观察性研究：肿瘤科患者入住重症监护病房后的病死率是否真的更高？
Marta Zafra Poves,Maria Angeles Vicente Conesa,Maria Esperanza Guirao García et al.
Marta Zafra Poves et al.
Background: Cancer patients often develop life-threatening events that prompt intensive care unit (ICU) admission. However, uncertainty regarding prognosis may hinder timely referral. We compared ICU survival in adults wi...
Marina de la Puente Alonso,Belén Rodríguez Sánchez,Luis Ángel Zamarro Díaz et al.
Marina de la Puente Alonso et al.
Purpose: Giant thick melanomas (GTMs) are rare tumors characterized by extreme size and depth. We aimed to describe their clinical features and outcomes. ...
Combined positive score status in metastatic triple-negative breast cancer patients treated with sacituzumab govitecan: associated clinical characteristics and testing patterns in a Central European cohort [0.03%]
转移性三阴性乳腺癌患者使用sacituzumab govitecan治疗的综合阳性评分状态：中欧队列中的相关临床特征和检测模式
Karolina Winsko-Szczęsnowicz,Małgorzata Pieniążek,Anna Polakiewicz-Gilowska et al.
Karolina Winsko-Szczęsnowicz et al.
Background: Programmed death ligand 1 (PD-L1) expression, assessed by the combined positive score (CPS), is an established predictive biomarker for first-line chemo-immunotherapy in metastatic triple-negative breast cance...